CM
KALA icon

Crestline Management’s KALA BIO KALA Stock Holding History

Crestline Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-37
Closed -$1.26M – 194
2018
Q2 		$1.26M Buy
37
+12
+48% +$460K 0.13% 180
2018
Q1 		$974K Buy
+25
New +$949K 0.12% 154
2017
Q4 		– Sell
-16
Closed -$888K – 185
2017
Q3 		$888K Buy
+16
New +$878K 0.12% 105

Other funds holding KALA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Crestline Management's KALA Position: Q3 2018 in Review

Crestline Management sold out of KALA BIO (KALA) in Q3 2018, closing a stake of 37 shares — an estimated $1.26M sold.

Crestline Management first reported a position in KALA in Q3 2017 and held it in 3 quarters. The position peaked at $1.26M in Q2 2018. 59 funds tracked by Wall St. Rank hold KALA as of Q3 2018.

  • Crestline Management reported no remaining KALA BIO position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 37 KALA BIO shares in Q3 2018, an estimated $1.26M.
  • Crestline Management first reported a position in KALA BIO in Q3 2017 and held it in 3 quarters.
  • Crestline Management's KALA BIO position peaked at $1.26M in Q2 2018.
  • 59 funds tracked by Wall St. Rank held KALA BIO as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.